Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Semorinemab (RO7105705) in Japanese Healthy Volunteers and Alzheimer's Disease Patients
jRCT2080224616Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semorinemab in Alzheimer's disease (AD) (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of semorinemab and Pharmacokinetics of semorinemab. Started Mar 2019; status: completed.
02
Drugs
semorinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080224616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224616.